Drug Trial Radar · NCT05740566
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
509
Actual
Start
May 31, 2023
Primary completion
Jan 29, 2025
Study completion Mar 26, 2028
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
Conditions
- Small Cell Lung Cancer (SCLC)
Interventions
TarlatamabDrug
Tarlatamab will be administered as an IV infusion.
LurbinectedinDrug
Lurbinectedin will be administered per local SOC.
TopotecanDrug
Topotecan will be administered per local SOC.
AmrubicinDrug
Amrubicin will be administered per local SOC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: From randomization up to minimum of death or primary completion DCO date 29 January 2025; median (min, max) time on the study was 8.6 (0.1, 18.5) months
Locations
223 sites in 31 countries. Site status is shown where the registry gives one.
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Alaska Oncology and Hematology
Anchorage, Alaska
University of Arkansas for Medical Sciences
Little Rock, Arkansas
University of California Los Angeles
Santa Monica, California
Northwestern University
Chicago, Illinois
University of Illinois Chicago
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
Pikeville Medical Center
Pikeville, Kentucky
Our Lady of the Lake Cancer Institute
Baton Rouge, Louisiana
Trinity Health Saint Joseph Mercy Ann Arbor
Ann Arbor, Michigan
University of Minnesota Cancer Center
Minneapolis, Minnesota
University of Missouri Health Care
Columbia, Missouri
Summit Medical Group, Overlook Oncology Center
Summit, New Jersey
New York University Grossman School of Medicine and New York University Langone Hospitals
New York, New York
Perlmutter Cancer Center at New York University Langone Hospital----Long Island
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Northport Veterans Affairs Medical Center
Northport, New York
Sanford Roger Maris Cancer Center
Fargo, North Dakota
Sanford Oncology Clinic and Pharmacy
Sioux Falls, South Dakota
University of Tennessee Medical Center Knoxville
Knoxville, Tennessee
Baptist Cancer Center
Memphis, Tennessee
Virginia Commonwealth University
Richmond, Virginia
Swedish Cancer Institute Medical Oncology
Edmonds, Washington
The Medical College of Wisconsin
Milwaukee, Wisconsin
Instituto Argentino de Diagnostico y Tratamiento IADT
Buenos Aires, Argentina
Sanatorio Allende
Córdoba, Argentina
Cemic
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Sociedad de Beneficencia Hospital Italiano
Córdoba, Córdoba Province, Argentina
Clinica Viedma
Viedma, Río Negro Province, Argentina
Sanatorio Parque SA
Rosario, Santa Fe Province, Argentina
Liverpool Hospital
Liverpool, New South Wales, Australia
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia
Monash Medical Centre
Clayton, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Medizinische Universitaet Graz
Graz, Austria
Universitaetsklinikum Krems
Krems, Austria
Universitair Ziekenhuis Gent
Ghent, Belgium
Jessa Ziekenhuis - Campus Virga Jesse
Hasselt, Belgium
Showing 40 of 223 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.